Condition: Metastatic Breast Cancer · Brain Metastases · Sponsor: Weill Medical College of Cornell University
Patients with metastatic breast cancer with at least 2 brain metastases will receive pembrolizumab every 3 weeks. Patients will undergo stereotactic radiosurgery (SRS) to one of the brain lesions. Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
This description comes directly from the study's public registry record.
Fabiana Gregucci, M.D. · 646-962-3110 · fgr4002@med.cornell.edu
Always discuss trial participation with your own doctor first.
| Weill Cornell Medicine | New York, New York, United States | Recruiting |
| Brooklyn Methodist Hospital - NewYork Presbyterian | New York, New York, United States | Recruiting |
| New York Presbyterian Hospital - Queens | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03449238